First Week of November 21st Options Trading For Recursion Pharmaceuticals

The article analyzes options strategies for Recursion Pharmaceuticals Inc (RXRX) at its current $5.12 share price, presenting potential risk-adjusted returns for institutional investors. Selling a $5.00 strike put for $0.80 offers a $4.20 cost basis if assigned, or a 98.91% annualized return if the contract expires worthless (60% probability). Conversely, a covered call strategy utilizing a $7.00 strike call against shares bought at $5.12 could yield a 42.58% total return if called away, or a 36.22% annualized yield boost if it expires worthless (60% probability), with implied volatilities of 115% for the put and 147% for the call, significantly higher than the 91% trailing 12-month actual volatility.

Analysis

The options market for Recursion Pharmaceuticals (RXRX) currently presents opportunities for yield generation and disciplined entry, reflecting significantly elevated implied volatility. At a share price of $5.12, selling a cash-secured put at the $5.00 strike for an $0.80 premium offers an effective entry point at $4.20 per share, a discount to the current market price. Analytical data suggests a 60% probability of this out-of-the-money put expiring worthless, which would translate to a 98.91% annualized return on the cash commitment. For investors holding or acquiring shares, a covered call strategy selling the $7.00 strike for a $0.30 premium could generate a total return of 42.58% if the stock is called away by the November 21st expiration. The probability of this call expiring worthless is also estimated at 60%, offering a 36.22% annualized yield boost in that scenario. A key takeaway is the discrepancy between implied volatility in the put (115%) and call (147%) contracts versus the actual trailing twelve-month volatility of 91%, indicating that options are priced for a larger move than has been historically observed, making premium-selling strategies mathematically attractive.

Key Decisions for Investors

• For investors bullish on RXRX but seeking a lower entry point, selling the $5.00 cash-secured put offers a disciplined way to either acquire shares at an effective cost of $4.20 or generate a substantial 98.91% annualized yield.
• Existing shareholders or new buyers can consider the covered call strategy against the $7.00 strike to generate a 36.22% annualized yield boost while retaining the shares, or to lock in a 42.58% total return, albeit capping further upside.